English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The GRPR-antagonist-based radioligands [ 67/68 Ga/ 111 In/ 177 Lu]NeoBOMB1 have shown excellent theragnostic profiles in preclinical prostate cancer models, while [ 68 Ga]NeoBOMB1 effectively visualized prostate cancer lesions in patients. We were further interested to explore the theragnostic potential of NeoBOMB1 in GRPR-positive mammary carcinoma, by first studying [ 67 Ga]NeoBOMB1 in breast cancer models; Methods: We investigated the profile of [ 67 Ga]NeoBOMB1, a [ 68 Ga]NeoBOMB1 surrogate, in GRPR-expressing T-47D cells and animal models; Results : NeoBOMB1 (IC 50 s of 2.2 ± 0.2 nM) and [ nat Ga]NeoBOMB1 (IC 50 s of 2.5 ± 0.2 nM) exhibited high affinity for the GRPR. At 37 °C [ 67 Ga]NeoBOMB1 strongly bound to the T-47D cell-membrane (45.8 ± 0.4% at 2 h), internalizing poorly, as was expected for a radioantagonist. [ 67 Ga]NeoBOMB1 was detected &gt;90% intact in peripheral mouse blood at 30 min pi. In mice bearing T-47D xenografts, [ 67 Ga]NeoBOMB1 specifically localized in the tumor (8.68 ± 2.9% ID/g vs. 0.6 ± 0.1% ID/g during GRPR-blockade at 4 h pi). The unfavorably high pancreatic uptake could be considerably reduced (206.29 ± 17.35% ID/g to 42.46 ± 1.31% ID/g at 4 h pi) by increasing the NeoBOMB1 dose from 10 pmol to 200 pmol, whereas tumor uptake remained unaffected. Notably, tumor values did not decline from 1 to 24 h pi; Conclusions: [ 67 Ga]NeoBOMB1 can successfully target GRPR-positive breast cancer in animals with excellent prospects for clinical translation.

molecules/molecules online/molecules annual

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice